6月29日，礼邦医药-B正式登陆港交所，盘中上涨80.53%，报41.26港元，成交额2.82亿港元。
消息面上，礼邦医药-B以每股22.60港元定价发行，公开发售阶段获963.56倍超额认购，国际配售获19.77倍认购，市场追捧力度强劲。公司引入GIC、Loomis Sayles、腾讯、RTW基金等11家基石投资者，合计认购约8150万美元，基石阵容创近年18A市场天花板。此前暗盘收涨约88%至94%，已充分反映市场对该标的的乐观预期。
礼邦医药是一家专注肾脏病领域的生物制药公司，拥有全球肾脏适应症覆盖范围最广的候选药物组合，核心产品AP301已完成中国关键III期临床，AP306已获突破性疗法认定，被市场称为"肾病创新药第一股"。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.